Cancer Management and Research · 2019 · 36 citations · 25 references
MedicineCancer BiologyOncologyBreast OncologyMolecular OncologyNeoplasiaCancer BiomarkersImmuno-oncology BiomarkersImmunohistochemistryMolecular Tumor ProfilingBreast Cancer PrognosisEstrogen Receptor ExpressionHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingIndoleamine 2, 3-Dioxygenase Pathway
BACKGROUND: Immune dysfunction in breast cancer patients is well established. Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme that is linked with progression of cancer. IDO is overexpressed in triple-negative breast cancer (TNBC) cases. MATERIALS AND METHODS: We conducted the first study to analyze IDO expression and overall survival in breast cancer cases in Pakistan. Expression of IDO, estrogen receptor (ER), progesterone receptor (PR), and human EGF receptor 2 (HER2) was evaluated by immunohistochemistry. Formalin-fixed paraffin-embedded breast cancer tissues of 100 (TNBC, n=49 and non-TNBC, n=51) patients were obtained from Shaukat Khanum Memorial Cancer Hospital and Research Centre. IDO expression was analyzed in association with clinicopathological features and overall survival. A total of 100 patients were classified based on the ordinal IDO score variables as low, medium, and high. In addition, overall mean age and SD of patients was 48.28±11.82. RESULTS: Immunohistochemical analysis showed that high IDO was observed in the TNBC patients (65.3%) compared to that in the non-TNBC patients (33.3%). Multivariable analyses showed that TNBC was an independent risk factor for high IDO expression. Overall survival was also significantly associated with IDO score. CONCLUSION: <0.01) and may suggest its role in disease pathogenesis. TNBC might be effectively treated with IDO inhibitors. Furthermore, high IDO expression is considerably associated with overall decreased patient survival. IDO might be utilized as a potential biomarker and immunotherapeutic target in breast cancer patients.
25
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
David H. Munn, Ebrahim Shafizadeh, John T. Attwood et al. · The Journal of Experimental Medicine · 1999 · 1.6K citations · Full text
Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division
Geon Kook Lee, Hyeon Jin Park, Megan K. L. MacLeod et al. · Immunology · 2002 · 432 citations · Full text